Biopharma firm Poseida Therapeutics racks up $142 mln Series C
San Diego-based Poseida Therapeutics, a biopharmaceutical company, has raised $142 million in Series C funding. Novartis Pharma AG led the round.
22 April 2019•1 min read
San Diego-based Poseida Therapeutics, a biopharmaceutical company, has raised $142 million in Series C funding. Novartis Pharma AG led the round.
